Evaluation of Endocan as a Treatment for Acute Inflammatory Respiratory Failure
Maxence Hureau,
Lucie Portier,
Méline Prin,
Patricia de Nadai,
Joanne Balsamelli,
Anne Tsicopoulos,
Daniel Mathieu,
Philippe Lassalle,
Bogdan Grigoriu,
Alexandre Gaudet,
Nathalie De Freitas Caires
Affiliations
Maxence Hureau
Univ. de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité de Lille, CHU Lille, Surgical Critical Care, Department of Anesthesiology and Critical Care, F-59000 Lille, France
Lucie Portier
Biothelis, F-59000 Lille, France
Méline Prin
Centre Hospitalier de Valenciennes, Laboratoire d’Anatomopathologie, F-59300 Valenciennes, France
Patricia de Nadai
Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France
Joanne Balsamelli
Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France
Anne Tsicopoulos
Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité de Lille, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de Compétence pour les Maladies Pulmonaires Rares, F-59000 Lille, France
Daniel Mathieu
Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité de Lille, CHU Lille, Pôle de Médecine Intensive—Réanimation, F-59000 Lille, France
Philippe Lassalle
Biothelis, F-59000 Lille, France
Bogdan Grigoriu
Service des Soins Intensifs et Urgences Oncologiques, Institut Jules Bordet, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium
Alexandre Gaudet
Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité de Lille, CHU Lille, Pôle de Médecine Intensive—Réanimation, F-59000 Lille, France
Background: Acute respiratory distress syndrome (ARDS) is a life-threatening condition resulting from acute pulmonary inflammation. However, no specific treatment for ARDS has yet been developed. Previous findings suggest that lung injuries related to ARDS could be regulated by endocan (Esm-1). The aim of this study was to evaluate the potential efficiency of endocan in the treatment of ARDS. Methods: We first compared the features of acute pulmonary inflammation and the severity of hypoxemia in a tracheal LPS-induced acute lung injury (ALI) model performed in knockout (Esm1−/−) and wild type (WT) littermate C57Bl/6 mice. Next, we assessed the effects of a continuous infusion of glycosylated murine endocan in our ALI model in Esm1−/− mice. Results: In our ALI model, we report higher alveolar leukocytes (p p p p Esm1−/− mice compared to WT mice. Continuous delivery of glycosylated murine endocan after LPS-induced ALI resulted in decreased alveolar leukocytes (p = 0.012) and neutrophils (p = 0.012), higher blood oxygenation levels (p p = 0.04), compared to mice treated with PBS. Conclusions: Endocan appears to be an effective treatment in an ARDS-like model in C57Bl/6 mice.
